197 related articles for article (PubMed ID: 25001119)
1. Role of empirical and targeted therapy in hospitalized patients with bloodstream infections caused by ESBL-producing Enterobacteriaceae.
Falcone M; Vena A; Mezzatesta ML; Gona F; Caio C; Goldoni P; Trancassini AM; Conti C; Orsi GB; Carfagna P; Stefani S; Venditti M
Ann Ig; 2014; 26(4):293-304. PubMed ID: 25001119
[TBL] [Abstract][Full Text] [Related]
2. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
[TBL] [Abstract][Full Text] [Related]
3. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
Huang SS; Lee MH; Leu HS
J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
[TBL] [Abstract][Full Text] [Related]
4. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
[TBL] [Abstract][Full Text] [Related]
5. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity.
To KK; Lo WU; Chan JF; Tse H; Cheng VC; Ho PL
Int J Infect Dis; 2013 Feb; 17(2):e120-4. PubMed ID: 23098812
[TBL] [Abstract][Full Text] [Related]
7. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae blood isolates with inducible AmpC β-lactamase.
Cheong HS; Ko KS; Kang CI; Chung DR; Peck KR; Song JH
Microb Drug Resist; 2012 Aug; 18(4):446-52. PubMed ID: 22409779
[TBL] [Abstract][Full Text] [Related]
9. Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections.
Qureshi ZA; Paterson DL; Pakstis DL; Adams-Haduch JM; Sandkovsky G; Sordillo E; Polsky B; Peleg AY; Bhussar MK; Doi Y
Int J Antimicrob Agents; 2011 Jan; 37(1):26-32. PubMed ID: 21075605
[TBL] [Abstract][Full Text] [Related]
10. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
[TBL] [Abstract][Full Text] [Related]
12. A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.
Gutiérrez-Gutiérrez B; Pérez-Galera S; Salamanca E; de Cueto M; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina J; Hernández A; Venditti M; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Natera C; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual A; Rodríguez-Baño J
Antimicrob Agents Chemother; 2016 Jul; 60(7):4159-69. PubMed ID: 27139473
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy.
Kang CI; Wi YM; Ko KS; Chung DR; Peck KR; Lee NY; Song JH
Scand J Infect Dis; 2013 Jul; 45(7):519-25. PubMed ID: 23509913
[TBL] [Abstract][Full Text] [Related]
14. Does Quick Sepsis-Related Organ Failure Assessment Suggest the Use of Initial Empirical Carbapenem Therapy in Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Bacteria? :A Multicenter Case-Control Study.
Mitsuboshi S; Tsuruma N; Watanabe K; Takahashi S; Nakashita M; Ito A; Kobayashi K; Tsugita M
Jpn J Infect Dis; 2019 Mar; 72(2):124-126. PubMed ID: 30381688
[TBL] [Abstract][Full Text] [Related]
15. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae.
Russo A; Falcone M; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale PL; Oliver A; Ruiz-Garbajosa P; Gasch O; Gozalo M; Pitout J; Akova M; Peña C; Cisneros JM; Hernández-Torres A; Farcomeni A; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Karaiskos I; de la Calle C; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Rodriguez-Gomez J; Souli M; Bonomo RA; Paterson DL; Carmeli Y; Pascual A; Rodríguez-Baño J; Venditti M;
Int J Antimicrob Agents; 2018 Nov; 52(5):577-585. PubMed ID: 29969692
[TBL] [Abstract][Full Text] [Related]
16. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems.
Fukuchi T; Iwata K; Kobayashi S; Nakamura T; Ohji G
BMC Infect Dis; 2016 Aug; 16(1):427. PubMed ID: 27538488
[TBL] [Abstract][Full Text] [Related]
17. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
[TBL] [Abstract][Full Text] [Related]
18. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
Ofer-Friedman H; Shefler C; Sharma S; Tirosh A; Tal-Jasper R; Kandipalli D; Sharma S; Bathina P; Kaplansky T; Maskit M; Azouri T; Lazarovitch T; Zaidenstein R; Kaye KS; Marchaim D
Infect Control Hosp Epidemiol; 2015 Aug; 36(8):981-5. PubMed ID: 25990361
[TBL] [Abstract][Full Text] [Related]
19. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases.
Endimiani A; Luzzaro F; Brigante G; Perilli M; Lombardi G; Amicosante G; Rossolini GM; Toniolo A
Antimicrob Agents Chemother; 2005 Jul; 49(7):2598-605. PubMed ID: 15980325
[TBL] [Abstract][Full Text] [Related]
20. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]